Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Exotic Automation & ... the launch of http://www.cng.exoticautomation.com , an ecommerce ... convenient way to purchase genuine OEM replacement CNG, ... , The new website provides owners of fleets ... access to high performance products for their vehicle ...
(Date:5/4/2015)... May 4, 2015 Many of us ... for certain infants with rare, inherited mutations of ... consequences of their impaired immune responses. ... identified an important role for calcium signaling in ... tuberculosis, the bacterium causing tuberculosis (TB). ...
(Date:5/4/2015)... TEL AVIV, Israel , May 4, 2015 /PRNewswire/ ... has filed its annual report on Form 20-F for ... U.S. Securities and Exchange Commission ("SEC"). The annual report ... for the development of antibodies in the area of ... antibodies with superior qualities of high specificity and binding ...
(Date:5/4/2015)... 2015 Genedata, a leading provider ... life science research, today announced the release of ... of its enterprise solution for biologics R&D. This ... efficient discovery and development of novel biotherapeutics. Version ... address protein optimization and developability requirements. Genedata will ...
Breaking Biology Technology:Exotic Automation & Supply Launches Ecommerce Website 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
... Web-based reporting credited with state's top healthcare ranking , , ... the state's web-based quality reporting system with the state's top ... Agency for Healthcare Research and Quality. , ,The ... quality score among all 50 states based on 129 measures ...
... company secrets. He thinks business meetings can be toxic as ... to improve the flow of communication, and he thinks employees ... , ,There is a method to Jason Fried's ... the recent Wisconsin Entrepreneurs' Conference in Milwaukee. , ,The founder ...
... - Using innovation to grow the top line will be ... 7:30 to 9 a.m., at the Butte des Morts Country ... open to the public, will center on innovation and adding value ... by Todd Teske, executive vice president and chief operating officer of ...
Cached Biology Technology:Visions: Chicago software exec Jason Fried breaks (almost) all the rules 2Visions: Chicago software exec Jason Fried breaks (almost) all the rules 3
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... follows form" might have been written to describe proteins, ... nature,s workhorse biomolecules enables each to carry out its ... X-ray protein crystallography, in which a beam of x-rays ... protein,s atoms, creating a diffraction pattern of dots that ...
... prescribed drugs for the treatment of heart failure are beta-blockers ... the heart,s workload. The drugs were thought to produce those ... study led by scientists at Temple University School of Medicine, ... counteracting the effects of an enzyme known as GRK2. The ...
... Nov. 5, 2013  The AVS has selected its major award ... to encourage excellence in research and innovation in technical areas ... award winners: Medard W. Welch Award— Dr. ... Barbara, "For seminal contributions to the theory of heterojunctions and ...
Cached Biology News:Bringing out the best in X-ray crystallography data 2Temple researchers uncover clues to how existing heart drugs work 2AVS Announces Its Major Award Winners of 2013 2AVS Announces Its Major Award Winners of 2013 3AVS Announces Its Major Award Winners of 2013 4AVS Announces Its Major Award Winners of 2013 5AVS Announces Its Major Award Winners of 2013 6
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... solid. PROTECT FROM LIGHT. Useful in cell activation experiments ... ≥98% by TLC. Soluble in DMSO or EtOH. ... 10 mM stock in DMSO is recommended. Microliter amounts ... O with rapid mixing (e.g. 10 μl into 5 ...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: